BioMarin Signs License Deal for Fabry Disease Therapy Candidate
BioMarin said it signed a license deal for a Fabry disease therapy candidate.
Related stories
Japan's Nikkei average falls 3%
M impact | EQUITY | Oct 30, 2026, 02:10 AM UTC
China 5G Communications Index Falls 5.7% to Near 11-Month Low
The CSI 5G Communications Index fell 5.7% in early trading, reaching its lowest level in nearly 11 months.
M impact | EQUITY | Oct 30, 2026, 01:56 AM UTC
Taiwan Benchmark Index Falls as Much as 3.5% to 44,726.26
Taiwan's benchmark stock index fell as much as 3.5% to 44,726.26, its lowest level since August 25.
M impact | EQUITY | Oct 30, 2026, 01:56 AM UTC
Beach Cities Commercial Bank Announces Third-Quarter 2026 Results
M impact | EQUITY | Oct 30, 2026, 01:55 AM UTC
Nikkei Index Falls 3%
M impact | EQUITY | Oct 30, 2026, 01:54 AM UTC
Chongqing Gas Q3 Net Profit Falls 88.27% Year Over Year
Chongqing Gas reported an 88.27% year-over-year decline in net profit for the first three quarters.
M impact | EQUITY | Oct 30, 2026, 01:54 AM UTC